BTC$59,014.00-1.44%
ETH$1,584.50-0.27%
USDT$0.9985-0.01%
BNB$549.09-1.23%
USDC$0.9996-0.01%
XRP$1.05-0.49%
SOL$74.71+0.18%
TRX$0.315-1.44%
FIGR_HELOC$1.01-2.94%
HYPE$65.29-0.62%
DOGE$0.0719-0.95%
RAIN$0.0158-0.91%
USDS$0.9996-0.01%
LEO$9.25-3.06%
XLM$0.2049+14.45%
ZEC$399.12-0.37%
BTC$59,014.00-1.44%
ETH$1,584.50-0.27%
USDT$0.9985-0.01%
BNB$549.09-1.23%
USDC$0.9996-0.01%
XRP$1.05-0.49%
SOL$74.71+0.18%
TRX$0.315-1.44%
FIGR_HELOC$1.01-2.94%
HYPE$65.29-0.62%
DOGE$0.0719-0.95%
RAIN$0.0158-0.91%
USDS$0.9996-0.01%
LEO$9.25-3.06%
XLM$0.2049+14.45%
ZEC$399.12-0.37%
Inhibrx shares surged over 60% after its cancer drug ozekibart showed a 52% reduction in disease progression, with FDA filing planned for Q2 2026.